Salarius Pharmaceuticals
$0.84
34
+$0.19+29.23% Wednesday 21:00
Statistics
Day High
0.9
Day Low
0.69
52W High
44.1
52W Low
0.51
Volume
5,962,438
Avg. Volume
3,777,690
Mkt Cap
4.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
14MayExpected
Expected EPS
-4.1208
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-11.15MNet Income
Analyst Ratings
$2.50Average Price Target
The highest estimate is 2.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow SLRX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
About
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Show more...
CEO
Mr. Mark J. Rosenblum CPA
Employees
2
Country
US
ISIN
US79400X4043
Listings
0 Comments
Share your thoughts
FAQ
What is Salarius Pharmaceuticals stock price today?▼
The current price of SLRX is $0.84 USD — it has increased by +29.23% in the past 24 hours. Watch Salarius Pharmaceuticals stock price performance more closely on the chart.
What is Salarius Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Salarius Pharmaceuticals stocks are traded under the ticker SLRX.
Is Salarius Pharmaceuticals stock price growing?▼
SLRX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Salarius Pharmaceuticals has showed a -92.29% decrease.
What is Salarius Pharmaceuticals market cap?▼
Today Salarius Pharmaceuticals has the market capitalization of 4.92M
What is Salarius Pharmaceuticals revenue for the last year?▼
Salarius Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Salarius Pharmaceuticals net income for the last year?▼
SLRX net income for the last year is -11.15M USD.
How many employees does Salarius Pharmaceuticals have?▼
As of April 02, 2026, the company has 2 employees.
In which sector is Salarius Pharmaceuticals located?▼
Salarius Pharmaceuticals operates in the Health Care sector.
When did Salarius Pharmaceuticals complete a stock split?▼
The last stock split for Salarius Pharmaceuticals was on August 18, 2025 with a ratio of 1:15.
Where is Salarius Pharmaceuticals headquartered?▼
Salarius Pharmaceuticals is headquartered in Houston, US.